Frequently Asked Questions

Some patients have heart failure with reduced ejection fraction (HFrEF). This condition is marked by decreased contractility, or the strength of the heart’s ability to squeeze to pump blood forward. In contrast, in HFpEF, the heart muscle is stiff, which limits the heart’s ability to fill. Signs of HFpEF may include:¹

• Shortness of breath, especially during activity or when lying down
• Fatigue
• Swelling of the legs or abdomen
• Chest discomfort
• Rapid or irregular heartbeat
• Coughing

You may consider a heart failure study if you or a loved one:

• Are between the ages of 40-85
• Have been diagnosed by a doctor with heart failure with preserved ejection fraction (HFpEF)
• Have not been diagnosed with hypertrophic cardiomyopathy, cardiac amyloidosis, Fabry disease, or Noonan syndrome
• Not be pregnant or breastfeeding

Additional qualification criteria apply. Study team will determine eligibility.

Participants in HFpEF clinical studies will be cared for by specialists who understand their unique situation and can help answer questions and address concerns from the participant or their loved ones. Throughout the duration of a trial, participants should expect to be monitored in a professional clinical environment, and have the opportunity to participate in scientific innovation.

Most clinical trials will involve screening to confirm that a potential patient is, in fact, a match for that study’s criteria. Once verified and the patient has signed an Informed Consent Form, which clearly provides the details and purpose of the study to that individual and what it involves, participants can expect to attend scheduled appointments at a study clinician’s site. They may also receive a study drug (also called an investigational medication) or potentially a placebo (which contains no active medication) and undergo additional screening and follow-up monitoring.

There is no cost to participate in a clinical trial. Participants receive all study-related medical care and medications for the duration of the study at no cost. Likewise in many instances, patients may also receive reimbursement for study-related travel.

As all drugs and medical procedures carry a risk of side effects, the possibility that participants may experience some discomfort or other reactions during or after a clinical trial does exist. The study staff for that trial should explain these potential risks before participants decide whether to participate, and help address any concerns.

No. Requirements or eligibility criteria vary by clinical trial, and sponsors/clinical sites are constantly looking for patient populations in order to test the efficacy of their investigational drugs. Further screening will determine whether a patient is eligible to participate in an active clinical study, but if not, they will likely be a candidate for one in the future, in which case that person may expect to be contacted. At that point, and before a potential participant decides whether to take part in the study, the study staff will review the informed consent form with them and answer any questions. Once the consent form has been signed by the participant, the screening period of the study begins.

Yes. Participation in clinical trials is entirely voluntary. Even if a participant is already involved in a study, they may change their mind at any time, for any reason.

If you are interested in learning more, please contact us at any time. You may email us at help@clinicalenrollment.com.